Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Epidermolysis Bullosa Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Epidermolysis Bullosa Overview | 9 | 1 |
| Pipeline Products for Epidermolysis Bullosa Comparative Analysis | 10 | 1 |
| Epidermolysis Bullosa Therapeutics under Development by Companies | 11 | 2 |
| Epidermolysis Bullosa Therapeutics under Investigation by Universities/Institutes | 13 | 1 |
| Epidermolysis Bullosa Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Epidermolysis Bullosa Products under Development by Companies | 17 | 1 |
| Epidermolysis Bullosa Products under Investigation by Universities/Institutes | 18 | 1 |
| Epidermolysis Bullosa Companies Involved in Therapeutics Development | 19 | 13 |
| Abeona Therapeutics, Inc. | 19 | 1 |
| Amryt Pharma plc | 20 | 1 |
| Berg LLC | 21 | 1 |
| Fibrocell Science, Inc. | 22 | 1 |
| GlaxoSmithKline Plc | 23 | 1 |
| InMed Pharmaceuticals Inc. | 24 | 1 |
| Karus Therapeutics Limited | 25 | 1 |
| ProQR Therapeutics N.V. | 26 | 1 |
| RegeneRx Biopharmaceuticals, Inc. | 27 | 1 |
| Scioderm, Inc. | 28 | 1 |
| Stratatech Corp | 29 | 1 |
| TWi Pharmaceuticals, Inc. | 30 | 1 |
| WAVE Life Sciences Ltd. | 31 | 1 |
| Epidermolysis Bullosa Therapeutics Assessment | 32 | 9 |
| Assessment by Monotherapy Products | 32 | 1 |
| Assessment by Target | 33 | 2 |
| Assessment by Mechanism of Action | 35 | 2 |
| Assessment by Route of Administration | 37 | 2 |
| Assessment by Molecule Type | 39 | 2 |
| Drug Profiles | 41 | 37 |
| allantoin Drug Profile | 41 | 3 |
| ALLO-ASC Drug Profile | 44 | 1 |
| Antisense Oligonucleotide 1 to Inhibit Keratin for Epidermolysis Bullosa Simplex Drug Profile | 45 | 1 |
| Antisense Oligonucleotide 2 to Inhibit Keratin for Epidermolysis Bullosa Simplex Drug Profile | 46 | 1 |
| Biologic for Epidermolysis Bullosa Drug Profile | 47 | 1 |
| birch bark extract Drug Profile | 48 | 3 |
| Cell Therapy for Dermatology and Immunology Drug Profile | 51 | 2 |
| Cell Therapy for Epidermolysis Bullosa Drug Profile | 53 | 1 |
| Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa Drug Profile | 54 | 1 |
| diacerein Drug Profile | 55 | 3 |
| EB-101 Drug Profile | 58 | 1 |
| EB-201 Drug Profile | 59 | 1 |
| FCX-007 Drug Profile | 60 | 3 |
| Gene Therapy for Epidermolysis Bullosa Drug Profile | 63 | 1 |
| Gene Therapy for Epidermolysis Bullosa Drug Profile | 64 | 1 |
| Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa Drug Profile | 65 | 1 |
| ICX-RHY Drug Profile | 66 | 2 |
| INM-750 Drug Profile | 68 | 1 |
| KA-1463 Drug Profile | 69 | 1 |
| QR-313 Drug Profile | 70 | 1 |
| RGN-137 Drug Profile | 71 | 2 |
| TXA-127 Drug Profile | 73 | 3 |
| ubidecarenone Drug Profile | 76 | 2 |
| Epidermolysis Bullosa Dormant Projects | 78 | 1 |
| Epidermolysis Bullosa Discontinued Products | 79 | 1 |
| Epidermolysis Bullosa Product Development Milestones | 80 | 9 |
| Featured News &Press Releases | 80 | 1 |
| Oct 01, 2016: Castle Creek Pharmaceuticals Announces Late-Breaking Results at EADV of Phase 2 Topical Diacerein 1% Data in Patients with Epidermolysis Bullosa Simplex | 80 | 1 |
| Sep 26, 2016: Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa | 81 | 1 |
| Sep 19, 2016: Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa | 81 | 1 |
| Sep 13, 2016: Amryt Pharma announces US patent for Lead Drug, Episalvan | 82 | 1 |
| Sep 08, 2016: Abeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa | 82 | 1 |
| Sep 07, 2016: Tarix Orphan Receives Orphan Drug Status for TXA127 for Genetic Skin Disorder Recessive Dystrophic Epidermolysis Bullosa | 83 | 1 |
| Jul 27, 2016: Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa | 84 | 1 |
| Jun 29, 2016: Fibrocell Announces Update on FCX-007 | 84 | 1 |
| Jun 27, 2016: Tarix Orphan Announces Positive Results with TXA127 in Animal Model of Dystrophic Epidermolysis Bullosa | 84 | 1 |
| Jun 13, 2016: Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa | 85 | 1 |
| Apr 18, 2016: Fibrocell and Intrexon Announce Allowance to Commence Phase I/II Trial for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa | 86 | 1 |
| Dec 04, 2015: RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment | 86 | 1 |
| Oct 08, 2015: Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for the Treatment of RDEB at American Society of Human Genetics Annual Meeting | 87 | 1 |
| Sep 25, 2015: Fibrocell and Intrexon Provide Regulatory Update for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa | 87 | 1 |
| Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment | 88 | 1 |
| Appendix | 89 | 2 |
| Methodology | 89 | 1 |
| Coverage | 89 | 1 |
| Secondary Research | 89 | 1 |
| Primary Research | 89 | 1 |
| Expert Panel Validation | 89 | 1 |
| Contact Us | 89 | 1 |
| Disclaimer | 90 | 1 |